Segment 3: Marine Biological Diversity beyond Areas of National Jurisdiction

Intellectual Property Rights and Marine Genetic Resources of the Areas beyond National Jurisdiction

Shotaro Hamamoto
Professor of the Law of International Organizations
Graduate School of Law, Kyoto University
http://www.hamamoto.law.kyoto-u.ac.jp/
hamamotolaw.kyoto-u.ac.jp
1. Decides to develop an international legally binding instrument under the United Nations Convention on the Law of the Sea on the conservation and sustainable use of marine biological diversity of areas beyond national jurisdiction and to that end:

2. Also decides that negotiations shall address the topics identified in the package agreed in 2011, namely the conservation and sustainable use of marine biological diversity of areas beyond national jurisdiction, in particular, together and as a whole, marine genetic resources, including questions on the sharing of benefits, measures such as area-based management tools, including marine protected areas, environmental impact assessments and capacity-building and the transfer of marine technology;
2. What use of marine genetic resources?

Example of “soil” genetic resources

Figure 2: Satoshi Ōmura searched for novel strains of Streptomyces bacteria as a source for new bioactive compounds. He isolated microbes from soil samples in Japan, cultured them in the laboratory (inset to left) and characterized many thousands of Streptomyces cultures. From those, he selected around 50 cultures that appeared most promising, and one of these cultures later turned out to be Streptomyces avermitilis (inset to right), the source of Avermectin.
2. What use of marine genetic resources?

Figure 3: William C. Campbell discovered that one of Ōmura’s Streptomycetes cultures was very effective in killing off parasites and the active compound, Avermectin, was purified. Avermectin was further modified to Ivermectin, which turned out to be highly effective in both animals and humans against a variety of parasites, including those that cause River Blindness and Lymphatic Filariasis.
3. What use of marine genetic resources?

<table>
<thead>
<tr>
<th>Nom</th>
<th>Application</th>
<th>Origine</th>
<th>Profondeur (en m)</th>
<th>Niveau d'étude</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discodermolide</td>
<td>Cancer</td>
<td>Éponge <em>Discodemia</em> sp.</td>
<td>140 Bahamas</td>
<td>Phase I</td>
</tr>
<tr>
<td>E 7389</td>
<td>Cancer</td>
<td>Éponge <em>Lissodendoryx</em> sp.</td>
<td>100 Nouvelle-Zélande</td>
<td>Phase I</td>
</tr>
<tr>
<td>Dictyostatin-1</td>
<td>Cancer</td>
<td>Éponge Ordre <em>Lithistida</em></td>
<td>440 Jamaïque</td>
<td>Préclinique</td>
</tr>
<tr>
<td>Sarcodictyn et dérivés</td>
<td>Cancer</td>
<td>Corail <em>Sarcodictyon roseum</em></td>
<td>Méditerranée</td>
<td>Préclinique</td>
</tr>
<tr>
<td>Salinosporamide A</td>
<td>Cancer</td>
<td><em>Actinomycète</em> <em>Salinospora</em> salin</td>
<td>&gt; 1 000 Pacifique</td>
<td>Préclinique</td>
</tr>
<tr>
<td>Topsentin</td>
<td>Cancer, Alzheimer</td>
<td>Éponge <em>Spongosporites ruetzleri</em></td>
<td>300-600 Bahamas</td>
<td>Préclinique</td>
</tr>
<tr>
<td>Implants orthopédiques</td>
<td>Greffe osseuse</td>
<td>Corail</td>
<td>&gt; 1 000 Pacifique</td>
<td>Préclinique</td>
</tr>
</tbody>
</table>

3. What use of marine genetic resources?

3. Why benefit sharing?

71. Divergent views were expressed on the relevant legal regime under the Convention regarding marine genetic resources beyond areas of national jurisdiction. Several delegations observed that, according to General Assembly resolution 2749 (XXV) and Part XI of the Convention, which they noted was part of customary international law, the seabed and ocean floor and the subsoil thereof beyond the limits of national jurisdiction (the “Area”), as well as its resources, were the common heritage of mankind. They emphasized that the common heritage of mankind, including the fair and equitable sharing of benefits, applied to the biological resources of the Area. Several delegations noted the competence of the International Seabed Authority in that regard. Some delegations also stressed that, under the Convention, the legal regime applicable to marine resources was defined by the maritime zone in which they were found, not by their nature as mineral or biological resources.

72. Other delegations stressed that Part XI only addressed mineral resources, and expressed the view that marine genetic resources beyond areas of national jurisdiction were regulated by the high seas regime in Part VII of the Convention. They observed that the mandate of the International Seabed Authority in relation to marine biological diversity was specifically set out in article 145 of the Convention relating to the protection of the marine environment with regard to activities in the Area.
3. Why benefit sharing?

Ten countries own 90% of the patent claims on marine microorganisms, with three of them (USA, Germany and Japan) owing 70% of the total.


[T]he question of the role played by patents in the context of benefit-sharing [is] of paramount importance to countries that could not conduct marine research on their own.

Intersessional workshops, May 2013, A/AC.276/6, para. 42.
4. What are the “benefits” to be shared?

1. Monetary benefits: Patents

   - A patent provides the holder with an exclusive right to an invention for a limited period of time.
   
   - Available for any inventions, whether products or processes, in all fields of technology, provided that:
     - they are new;
     - they involve an inventive step; and
     - they are capable of industrial application [TRIPs, Art. 27(1)]

   - Microorganisms isolated from naturally occurring substance may be patented.

2. Non-monetary benefits: Technology transfer / cooperation
5. Where should the question be discussed?

I. INTRODUCTION ........................................................................................................................................ 2

II. ISSUES RELATING TO THE PATENT PROVISIONS OF ARTICLE 27.3(B) ........................................ 2
A. General Issues ........................................................................................................................................ 2
B. Scope of exceptions to patentability in Article 27.3(B) ....................................................................... 7
C. Ethical exceptions to patentability and Article 27.2 ........................................................................... 10
D. Conditions of patentability in Article 27.1 and plant and animal inventions ....................................... 12

III. ISSUES RELATING TO THE SUI GENERIS PROTECTION OF PLANT VARIETIES ........................................ 14
A. General issues with respect to plant variety protection ................................................................. 14
B. "Effective sui generis systems" of protection ..................................................................................... 16
C. Relationship between the TRIPS requirement to have an effective sui generis system and the UPOV Convention .................................................................................................................... 20
D. Relationship between sui generis protection of plant varieties and traditional knowledge and farmers' rights ................................................................. 23

IV. TRANSFER OF TECHNOLOGY ........................................................................................................ 24

WTO, Review of the Provisions of Article 27.3(B), Note by the Secretariat, 9 March 2006, IP/C/W/369/Rev.1.
5. Where should the question be discussed?

**Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore**

Twenty-Eighth Session
Geneva, July 7 to 9, 2014

CONSOLIDATED DOCUMENT RELATING TO INTELLECTUAL PROPERTY AND GENETIC RESOURCES

Article 3: Disclosure requirement
Article 8: Due diligence

No reference to BBNJ
5. Where should the question be discussed?

**GLOBAL MULTILATERAL BENEFIT-SHARING MECHANISM**

Parties shall consider the need for and modalities of a global multilateral benefit-sharing mechanism to address the fair and equitable sharing of benefits derived from the utilization of genetic resources and traditional knowledge associated with genetic resources that occur in transboundary situations or for which it is not possible to grant or obtain prior informed consent. The benefits shared by users of genetic resources and traditional knowledge associated with genetic resources through this mechanism shall be used to support the conservation of biological diversity and the sustainable use of its components globally.

**Nagoya Protocol** on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity (entered into force in 2014)
28. Several participants were of the view that access to genetic resources in areas beyond national jurisdiction, such as the high seas, the deep seabed or Antarctica, would constitute a situation where it is not possible to grant or obtain PIC. However, a number of other participants noted that Article 10 must be within the scope of the CBD and the Nagoya Protocol, which excludes its application to areas beyond national jurisdiction. They substantiated their views with reference to Article 15 of the CBD and Articles 3 and 4 of the Protocol.


Article 4. Jurisdictional Scope

Subject to the rights of other States, and except as otherwise expressly provided in this Convention, the provisions of this Convention apply, in relation to each Contracting Party:

(a) In the case of components of biological diversity, in areas within the limits of its national jurisdiction; and

(b) In the case of processes and activities, regardless of where their effects occur, carried out under its jurisdiction or control, within the area of its national jurisdiction or beyond the limits of national jurisdiction.
5. Where should the question be discussed?

(388) The Meeting thanked the Netherlands for this update. In responding to the possible negotiation of a relevant instrument to the Antarctic Treaty area, several Parties highlighted that the collection and use of biological material from the Antarctic should be discussed within the Antarctic Treaty System. It was noted that Parties should be mindful of the regulatory system of the Antarctic Treaty System and be careful of engaging in discussions on the possible application of other, possibly conflicting, regimes. The Meeting reaffirmed that the Antarctic Treaty System was the appropriate framework for managing the collection of biological materials in the Antarctic Treaty area and for considering its use. Many Parties underlined the importance of keeping biological prospecting on the agenda of the ATCM.

6. How should the benefits be shared?

1. “kick-off” problem: disclosure of origin

2. Possible mechanisms
   (a) Open innovation approach
   (b) IP protection + trust fund

3. Monitoring mechanism & dispute settlement procedure
6. How should the benefits be shared?

1. “Kick-off” problem: disclosure of origin

Applicants should be obliged to disclose that they obtained the MGRs in question in ABNJ.

The consequences for lack of disclosure:
- invalidity of the patent?
- unenforceability of the patent in infringement cases?
6. How should the benefits be shared?

2. Possible mechanisms
   (a) Open innovation approach

- A radical approach: denial of patentability
- A moderate approach: a patent version of “copyleft”?

☐ Everyone can use the data or information

☒ No use for developing States having no cutting-edge pharmaceutical or chemical industry

☒ Little incentive for innovation?

☒ Encourages false declarations?
6. How should the benefits be shared?

2. Possible mechanisms
   (b) IP protection + trust fund

Developers of a commercial product using MGRs from ABNJ are required to pay royalties to the Fund.

The Fund would be used to protect BBNJ.

Who should manage the Fund? ISA?

6. How should the benefits be shared?

3. Monitoring mechanisms and dispute settlement procedures

How to monitor whether the obligation to disclose the origin is implemented?

What kind of dispute settlement procedures in cases where sanctions (invalidity or unenforceability of the patent) are imposed?